Indapta Therapeutics, Inc. is a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. Headquartered in San Francisco, Indapta was founded in 2017 by Guy DiPierro along with Ronald Martell and scientists at the University of California, Davis, and Stanford University. The company has developed allogeneic FcRIγ-deficient natural killer cells, known as G-NK cells, and is working to bring this off-the-shelf cell therapy to patients to address the limitations of currently available autologous T-cell therapies.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $22.5M
Investors 2
| Date | Name | Website |
| - | Myeloma In... | myelomainv... |
| 17.02.2022 | RA Capital... | racap.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.12.2024 | - | $22.5M | - |
Mentions in press and media 5
| Date | Title | Description |
| 26.12.2024 | Houston startup secures $22.5M to innovate cell therapy to fight cancer | A promising cell therapy company has raised its latest funding round — to the tune of $22.5 million. Indapta Therapeutics, which has a dual headquarters in Houston and Seattle, is a clinical stage biotechnology and next-generation cell ther... |
| 17.12.2024 | Indapta Therapeutics Raises $22.5M in Funding | Indapta Therapeutics, a Houston, TX and Seattle, WA-based clinical stage biotechnology company, raised $22.5M in funding. The round was led by RA Capital Management, LP, Leaps by Bayer, Vertex Ventures HC, Pontifax, and the Myeloma Investme... |
| 11.02.2022 | OpenSea illustrates the perils of growing too fast | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Hi Term Sheet readers. Fortune finance editor Lee Clifford here filling for in Jessica Mathews to... |
| 11.02.2022 | OpenSea illustrates the perils of growing too fast | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Hi Term Sheet readers. Fortune finance editor Lee Clifford here filling for in Jessica Mathews to... |
| - | Indapta Therapeutics | “Indapta” |